CSL Behring LLC

• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending
  2024-518821-13-00 Phase II 10 countries HUMAN NORMAL IMMUNOGLOBULIN
• Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease Pending
  2025-521154-42-00 Phase II 4 countries ANUMIGILIMAB
• Phase 4, double-blind study evaluating the response on computed tomography (CT) lung density decline rates of Respreeza / Zemaira weekly for… Pending
  2025-522964-33-00 Phase IV 1 country HUMAN ALPHA1-PROTEINASE INHIBITOR
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 Phase II 11 countries VAMIFEPORT TRIHYDROCHLORIDE
• Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults with Hemophilia B with Pretreatment Adeno-associated Virus … Recruiting
  2023-509590-23-00 Phase III 2 countries ETRANACOGENE DEZAPARVOVEC
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 Phase II/III 22 countries CLAZAKIZUMAB
• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe He… Recruiting
  2023-505805-18-00 Phase III 4 countries ETRANACOGENE DEZAPARVOVEC
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Ended
  2024-517757-27-00 Phase IV 1 country GARADACIMAB
• Long-term Follow-up Study of Male Adults with Hemophilia B Previously Treated with Etranacogene Dezaparvovec (CSL222) Ended
  2023-503765-37-00 Phase II/III 6 countries ETRANACOGENE DEZAPARVOVEC
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended
  2024-513440-29-00 Phase II/III 7 countries HEMOPEXIN, HUMAN
• CSL312_3003 Safety and Pharmacokinetic study in Subjects 2 to 11 Years of Age with Hereditary Angioedema Ended
  2022-502386-13-00 Phase III 2 countries GARADACIMAB
• Long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks Ended
  2024-510777-18-00 Phase III 5 countries GARADACIMAB
• A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult pat… Ended
  2024-512603-39-00 Phase I (FiH) 2 countries ETRANACOGENE DEZAPARVOVEC
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 Phase III 7 countries HUMAN NORMAL IMMUNOGLOBULIN
• The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft‑versus-host disease (GVHD) in patients receiving hematopoie… Ended
  2024-511164-92-00 Phase II/III 3 countries HUMAN ALPHA1-PROTEINASE INHIBITOR
• A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B,… Ended
  2024-510738-42-00 Phase III 6 countries ETRANACOGENE DEZAPARVOVEC
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in post-COVID-19 POTS Ended
  2023-508744-22-00 Phase III 3 countries HUMAN NORMAL IMMUNOGLOBULIN; HUMAN PLASMA PROTEIN

Showing 1–17 of 17 trials